China Pharma Holdings, Inc. (CPHI:NYSEMKT) closed at $0.710 on October 16, 2026, down 2.47% on the day. The stock trades 96.3% below its 52-week high of $19.19 and 86.8% above its 52-week low of $0.380. Over the past year, it lost 61.0%. China Pharma Holdings, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -18.31% | -0.01% | -21.99% | +5.96% | -60.99% |
In 252 trading sessions since October 16, 2025, CPHI closed higher on 94 days (37%). Its best day was July 21, 2026 (+790.11%) and its worst was July 22, 2026 (-78.89%). The stock moved 10% or more in a single session 26 times. It opened at least 5% above the previous day's high 5 times.
China Pharma Holdings, Inc., together with its subsidiaries, develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. It offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions, and granules. The company's products are used for the treatment of central nervous system and cerebral-cardiovascular, anti-infection and respiratory, and digestive and other diseases. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and surgery-thrombus deep phlebitis; and Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and lipoprotein blood diseases. The company also provides Bumetanide to treat edema diseases; Candesartan for hypertension; Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract in...
Find more stocks like CPHI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.